News & Analysis as of

Clinical Trials Coherus

Goodwin

Coherus Announces Positive Results for CHS-1420, Humira Biosimilar Candidate

Goodwin on

Coherus reported that its proposed adalimumab (Humira) biosimilar candidate demonstrated clinical equivalence on all endpoints compared to the European marketed Humira. The candidate in this study also did not show any...more

Goodwin

Coherus Announces Humira Biosimilar PK Clinical Bioequivalence Results

Goodwin on

Yesterday, Coherus announced that CHS-1420, its proposed biosimilar of Humira® (adalimumab), met the primary endpoint in a clinical pharmacokinetic (PK) bioequivalence study that compared CHS-1420 to Humira. According to...more

Goodwin

Coherus Announces Positive Topline Phase III Results for its Humira Biosimilar

Goodwin on

Coherus Biosciences announced “positive topline 24-week treatment phase three results” in patients with psoriasis for CHS-1420, its proposed biosimilar to Humira® (adalimumab). Coherus stated that it anticipates filing its...more

3 Results
 / 
View per page
Page: of 1

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide